144 related articles for article (PubMed ID: 16521658)
1. COX-2 inhibitors and heart.
Manoria P; Manoria PC
Indian Heart J; 2005; 57(6):772-7. PubMed ID: 16521658
[No Abstract] [Full Text] [Related]
2. The COX-2 inhibitors--an update.
Furberg CD
Am Heart J; 2006 Aug; 152(2):197-9. PubMed ID: 16875896
[No Abstract] [Full Text] [Related]
3. COX-2 selective inhibitors and heart health.
Simon LS; White WB
Postgrad Med; 2005 Jan; 117(1 Suppl):7-20. PubMed ID: 19667717
[TBL] [Abstract][Full Text] [Related]
4. Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
Couzin J
Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414
[No Abstract] [Full Text] [Related]
5. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
Spalding WM; Reeves MJ; Whelton A
Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
[TBL] [Abstract][Full Text] [Related]
6. Cardiac risks with COX-2 inhibitors.
Ashworth AJ
CMAJ; 2007 Feb; 176(4):489-92. PubMed ID: 17296963
[No Abstract] [Full Text] [Related]
7. Clinical inquiries. Do COX-2 inhibitors worsen renal function?
Wall R; Strickland C; Jamieson B; Lo V
J Fam Pract; 2007 Nov; 56(11):957-8. PubMed ID: 17976347
[No Abstract] [Full Text] [Related]
8. COX-2 inhibitors and the heart: putting risk in perspective.
Bobadilla RV; Barnett EM; Randels CL
Adv Nurse Pract; 2005 Nov; 13(11):48-50. PubMed ID: 16295003
[No Abstract] [Full Text] [Related]
9. [Cardiovascular risks of Cox-2-antagonists. Opinion on the marketed name rofecoxib, and its market-withdrawn valdecoxib and the actual therapeutic restrictions].
Bolten WW; Reiter S;
Z Rheumatol; 2005 May; 64(4):286-9. PubMed ID: 15909092
[No Abstract] [Full Text] [Related]
10. Rofecoxib 50 mg and valdecoxib 20 or 40 mg in adults and adolescents with postoperative pain after third molar extraction: results of two randomized, double-blind, placebo-controlled, single-dose studies.
Daniels SE; Desjardins PJ; Bird SR; Smugar SS; Tershakovec AM
Clin Ther; 2006 Jul; 28(7):1022-34. PubMed ID: 16990080
[TBL] [Abstract][Full Text] [Related]
11. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2.
Fries S; Grosser T; Price TS; Lawson JA; Kapoor S; DeMarco S; Pletcher MT; Wiltshire T; FitzGerald GA
Gastroenterology; 2006 Jan; 130(1):55-64. PubMed ID: 16401468
[TBL] [Abstract][Full Text] [Related]
12. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
[TBL] [Abstract][Full Text] [Related]
13. Concern about one drug or entire class of drugs.
Curković B
Reumatizam; 2005; 52(1):5-6. PubMed ID: 16689104
[No Abstract] [Full Text] [Related]
14. Cerebrovascular events after discontinuation of rofecoxib treatment.
Andersohn F
Cardiovasc Drugs Ther; 2007 Apr; 21(2):77-9. PubMed ID: 17404824
[No Abstract] [Full Text] [Related]
15. Is the demonstration of adenoma reduction with rofecoxib a pyrrhic victory?
Lynch PM
Gastroenterology; 2006 Dec; 131(6):2003-5. PubMed ID: 17188962
[No Abstract] [Full Text] [Related]
16. COX-2 inhibitors and cardiovascular risk.
Salzberg DJ; Weir MR
Subcell Biochem; 2007; 42():159-74. PubMed ID: 17612050
[TBL] [Abstract][Full Text] [Related]
17. Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis.
Cunnington M; Webb D; Qizilbash N; Blum D; Mander A; Funk MJ; Weil J
Pharmacoepidemiol Drug Saf; 2008 Jun; 17(6):601-8. PubMed ID: 18383442
[TBL] [Abstract][Full Text] [Related]
18. Balancing the cyclooxygenase portfolio.
Armstrong PW
CMAJ; 2006 May; 174(11):1581-2. PubMed ID: 16717266
[No Abstract] [Full Text] [Related]
19. COX-2 inhibitors and pain after oral surgery - pertinent papers 2002-2003.
Meechan J
Br J Oral Maxillofac Surg; 2006 Apr; 44(2):163-5. PubMed ID: 16191457
[No Abstract] [Full Text] [Related]
20. [Rofecoxib (Vioxx) has been withdrawn, what next?].
Idänpään-Heikkilä JE; Klaukka T
Duodecim; 2004; 120(21):2489-90. PubMed ID: 15631403
[No Abstract] [Full Text] [Related]
[Next] [New Search]
